Biochemical Engineering Special Interest Group
biological engineering professionals
25 January 2018

Synpromics and UCL ally to aim gene therapies at blood-based diseases

Synpromics has entered into another gene therapy collaboration with UCL. This time around the aim is to apply Synpromics’ synthetic promoter expertise to the development of gene therapies against diseases affecting the blood. Working with Adrian Thrasher, M.D, Ph.D., and his clinical research group at the UCL Great Ormond Street Institute of Child Health, Synpromics plans to create tissue-specific promoters. These promoters will be tailored to use in lymphoid, myeloid, microglia and other specialized immune cells. Synpromics sees the promoters being used in gene-modified cell therapies, such as treatments that use microglia cells to deliver proteins. Fierce Biotech 25/1/2018

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).